Erlotinib Krka
EGFR tyrosine kinase inhibitor for non-small cell lung cancer and pancreatic cancer
Erlotinib Krka is a targeted cancer medication that works by blocking the epidermal growth factor receptor (EGFR), a protein involved in cancer cell growth and spread. It is prescribed for adults with advanced non-small cell lung cancer (NSCLC) harbouring specific EGFR mutations, and in combination with gemcitabine for metastatic pancreatic cancer. This comprehensive guide covers dosage, side effects, drug interactions, and important safety information.
Quick Facts
Key Takeaways
- Erlotinib Krka selectively targets EGFR and is most effective in NSCLC tumours with specific EGFR mutations (exon 19 deletions or exon 21 L858R).
- Must be taken on an empty stomach — at least 1 hour before or 2 hours after food — to ensure proper absorption.
- Skin rash and diarrhoea are the most common side effects; severe diarrhoea and interstitial lung disease require immediate medical attention.
- Smoking significantly reduces erlotinib blood levels; patients must stop smoking during treatment.
- Multiple drug interactions exist — inform your doctor about all medications, especially antifungals, antibiotics, antiepileptics, and anticoagulants.
What Is Erlotinib Krka and What Is It Used For?
Quick Answer: Erlotinib Krka is a targeted anticancer medicine containing erlotinib, an EGFR tyrosine kinase inhibitor. It is used to treat advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations and metastatic pancreatic cancer (in combination with gemcitabine).
Erlotinib Krka belongs to a class of drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. The active substance, erlotinib, works by blocking the activity of the EGFR protein, which plays a central role in the signalling pathways that drive cancer cell proliferation, survival, migration, and resistance to programmed cell death (apoptosis). By inhibiting EGFR, erlotinib helps to slow or stop the growth and spread of cancer cells.
This medication is approved for use in adults for two primary indications. The first and most important indication is the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 80–85% of all lung cancers and is one of the leading causes of cancer death worldwide. Erlotinib Krka may be prescribed as a first-line treatment for patients whose tumours harbour activating EGFR mutations, or as a maintenance therapy when the disease has not progressed after initial platinum-based chemotherapy, provided the tumour has EGFR-activating mutations. It may also be used as a subsequent-line therapy after failure of at least one prior chemotherapy regimen.
The second approved indication is the treatment of metastatic pancreatic cancer, where Erlotinib Krka is used in combination with gemcitabine chemotherapy. Pancreatic cancer remains one of the most challenging malignancies, with limited treatment options. Clinical trials have demonstrated a modest but statistically significant survival benefit when erlotinib is added to gemcitabine in this setting.
EGFR mutation testing is essential before starting erlotinib for NSCLC. The most common EGFR-activating mutations are exon 19 deletions (del19) and the exon 21 L858R point mutation, which together account for approximately 85–90% of all sensitising EGFR mutations. These mutations make the tumour particularly responsive to EGFR tyrosine kinase inhibitors such as erlotinib. Modern guidelines from organisations including the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) recommend EGFR testing as a standard part of the diagnostic workup for advanced NSCLC.
Erlotinib Krka is a generic version of the original erlotinib product. It contains the same active substance and works in the same way. Other approved generic brands include Erlotinib Sandoz and Erlotinib STADA. Your doctor will determine which erlotinib product is appropriate for your treatment.
What Should You Know Before Taking Erlotinib Krka?
Quick Answer: Before starting erlotinib, inform your doctor about all medical conditions, particularly liver or kidney disease, lung problems, and eye disorders. Do not take erlotinib if you are allergic to it. Avoid pregnancy and breastfeeding during treatment.
Contraindications
Do not take Erlotinib Krka if you are allergic (hypersensitive) to erlotinib or any of the other ingredients in the tablets. The inactive ingredients include lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose, sodium laurilsulfate, sodium starch glycolate, calcium silicate, and magnesium stearate, with a film coating containing hypromellose, propylene glycol, titanium dioxide, talc, and iron oxide pigments.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine due to the presence of lactose. This medicine contains less than 1 mmol (23 mg) sodium per tablet and is therefore essentially sodium-free.
Warnings and Precautions
Several important warnings apply to patients taking Erlotinib Krka. Before starting treatment, have a thorough discussion with your doctor about your complete medical history. The following conditions require special attention and monitoring:
Interstitial lung disease (ILD): This is a serious and potentially fatal complication that has been reported with erlotinib use. ILD occurs in approximately 1 in 100 European patients and up to 1 in 10 Japanese patients. If you develop sudden onset of breathing difficulties accompanied by cough and fever, stop taking erlotinib and contact your doctor immediately. These symptoms could indicate ILD, which requires prompt medical evaluation and treatment.
Liver problems: Erlotinib can cause serious liver damage, including hepatitis and liver failure, which has been fatal in rare cases. Your doctor will perform regular blood tests to monitor your liver function throughout treatment. Inform your doctor immediately if you develop symptoms such as jaundice (yellowing of the skin or eyes), dark urine, nausea, vomiting, or abdominal pain. Treatment with erlotinib is not recommended if you have severe liver disease.
Gastrointestinal perforation: Uncommon but serious perforations of the gastrointestinal tract have been observed. The risk may be increased in patients with a history of peptic ulcer disease or diverticular disease. Tell your doctor if you experience severe abdominal pain.
Diarrhoea: This is one of the most common side effects and can be severe. Your doctor may prescribe anti-diarrhoeal medication such as loperamide. If you experience severe or persistent diarrhoea, nausea, loss of appetite, or vomiting, contact your doctor as treatment may need to be interrupted and hospitalisation may be required. Severe diarrhoea can lead to low potassium levels and impaired kidney function, particularly in patients receiving concurrent chemotherapy.
Eye disorders: If you wear contact lenses or have a history of eye problems such as severe dry eyes, corneal inflammation, or corneal ulcers, tell your doctor before starting treatment. Contact your doctor or nurse immediately if you develop acute or worsening eye redness and pain, increased tearing, blurred vision, or light sensitivity, as you may need urgent ophthalmological care. Rare cases of corneal ulceration and perforation have been reported.
Kidney disease: It is not known whether erlotinib has a different effect in patients with impaired renal function. Treatment is not recommended for patients with severe kidney disease.
Gilbert's syndrome: Patients with glucuronidation disorders such as Gilbert's syndrome should be treated with caution due to potential effects on drug metabolism.
You should stop smoking while being treated with Erlotinib Krka. Smoking induces the CYP1A2 enzyme, which metabolises erlotinib, and can reduce drug blood levels by up to 50–60%. This reduction in drug exposure may significantly decrease the effectiveness of your cancer treatment. Discuss smoking cessation options with your doctor.
Pregnancy and Breastfeeding
Erlotinib Krka should not be used during pregnancy. Animal studies have shown reproductive toxicity, and the drug's mechanism of action suggests potential harm to the developing foetus. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose.
If you become pregnant while taking Erlotinib Krka, inform your doctor immediately. Your oncologist will discuss the risks and benefits and decide whether treatment should continue based on your individual situation.
Breastfeeding is not recommended during treatment with erlotinib and for at least 2 weeks after the last dose. It is not known whether erlotinib passes into breast milk, but given the potential risks to the infant, breastfeeding should be discontinued.
Driving and Using Machines
Erlotinib Krka has not been specifically studied for its effects on the ability to drive or use machines, and such effects are unlikely from the drug itself. However, individual side effects such as fatigue, visual disturbances, or nausea may impair your ability to drive or operate machinery. You should assess your own fitness before undertaking these activities.
How Does Erlotinib Krka Interact with Other Drugs?
Quick Answer: Erlotinib has significant interactions with many medications. CYP3A4 inhibitors (such as ketoconazole) increase erlotinib levels, while CYP3A4 inducers (such as rifampicin) decrease them. Acid-reducing agents reduce erlotinib absorption. Warfarin and statins require careful monitoring when used with erlotinib.
Erlotinib is primarily metabolised by the cytochrome P450 enzymes CYP3A4 and CYP1A2. This means that other medications which affect these enzymes can significantly alter erlotinib blood levels, potentially increasing toxicity or reducing effectiveness. It is essential to inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements.
Major Interactions
| Drug / Class | Effect on Erlotinib | Clinical Action |
|---|---|---|
| Ketoconazole, itraconazole (antifungals) | Increases erlotinib levels (CYP3A4 inhibition) | Dose reduction may be required; close monitoring |
| Rifampicin, rifabutin (antibiotics) | Significantly decreases erlotinib levels (CYP3A4 induction) | Avoid combination; alternative treatments recommended |
| Phenytoin, carbamazepine, barbiturates (antiepileptics) | Decreases erlotinib levels (CYP3A4 induction) | Avoid combination if possible; consider alternatives |
| St. John’s Wort (herbal supplement) | Decreases erlotinib levels (CYP3A4 induction) | Do not use during erlotinib treatment |
| Warfarin (anticoagulant) | Erlotinib increases bleeding tendency | Regular INR monitoring required; dose adjustment |
| Omeprazole, ranitidine (acid reducers) | Decreases erlotinib absorption (pH-dependent) | Avoid proton pump inhibitors; use antacids with timing separation |
Minor Interactions
| Drug / Class | Effect | Clinical Action |
|---|---|---|
| Erythromycin, clarithromycin (antibiotics) | May increase erlotinib levels (moderate CYP3A4 inhibition) | Monitor for increased side effects |
| Ciprofloxacin (antibiotic) | May increase erlotinib levels (CYP1A2 inhibition) | Monitor for increased side effects |
| Statins (cholesterol-lowering) | Erlotinib may increase risk of statin-related myopathy | Report unexplained muscle pain, tenderness, or weakness |
| Proteasome inhibitors | May alter erlotinib levels | Close clinical monitoring |
The interaction between erlotinib and acid-reducing agents is particularly important. Erlotinib requires an acidic gastric environment for optimal dissolution and absorption. Proton pump inhibitors (PPIs) such as omeprazole and esomeprazole significantly reduce erlotinib absorption and should be avoided. If acid-reducing therapy is necessary, antacids should be taken at least 2 hours before or 1 hour after erlotinib. H2-receptor antagonists such as ranitidine should be used with caution and taken at staggered times.
What Is the Correct Dosage of Erlotinib Krka?
Quick Answer: The recommended dose is 150 mg once daily for non-small cell lung cancer and 100 mg once daily for pancreatic cancer (combined with gemcitabine). Take on an empty stomach, at least 1 hour before or 2 hours after food.
Always take Erlotinib Krka exactly as your doctor has prescribed. The dosage depends on the type of cancer being treated, and your doctor may adjust the dose based on how well you tolerate the medication. Dose reductions are made in 50 mg steps. Erlotinib Krka is available in 25 mg, 100 mg, and 150 mg film-coated tablets to allow for flexible dosing.
Adults
Non-Small Cell Lung Cancer (NSCLC)
The recommended dose is 150 mg once daily, taken on an empty stomach. This applies to both first-line treatment of EGFR-mutated NSCLC and maintenance or subsequent-line therapy. Treatment should be continued until disease progression or unacceptable toxicity occurs.
Metastatic Pancreatic Cancer
The recommended dose is 100 mg once daily, taken on an empty stomach. Erlotinib is administered in combination with gemcitabine chemotherapy. The gemcitabine dosing schedule is determined by your oncologist.
The tablet must be taken at least 1 hour before or 2 hours after eating. Swallow the tablet whole with water. Do not crush, chew, or split the tablet. Taking erlotinib with food significantly increases its absorption and may lead to higher blood levels and increased side effects. Consistency in timing relative to meals is important for stable drug levels.
Children and Adolescents
Erlotinib Krka has not been studied in patients under 18 years of age. Treatment with this medicine is not recommended for children and adolescents. There are no established paediatric indications for erlotinib, and safety and efficacy data in this population are lacking.
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients may be more susceptible to certain side effects, particularly diarrhoea and dehydration. Close monitoring is recommended, and dose adjustments should be made based on individual tolerability. Your doctor will assess your overall health status, kidney and liver function, and other medications when determining the appropriate dose.
Missed Dose
If you forget to take a dose of Erlotinib Krka, contact your doctor or pharmacist as soon as possible for guidance. Do not take a double dose to make up for a missed dose. Simply resume your regular dosing schedule with the next planned dose. Consistent daily dosing is important for maintaining effective drug levels.
Overdose
If you take more Erlotinib Krka than prescribed, contact your doctor or hospital emergency department immediately. An overdose may lead to an increase in the severity of known side effects, particularly skin rash, diarrhoea, and liver enzyme elevations. There is no specific antidote for erlotinib overdose; treatment is supportive and symptomatic. Your doctor may need to interrupt or discontinue treatment depending on the clinical situation.
It is important to continue taking Erlotinib Krka every day for as long as your doctor prescribes it. Do not stop treatment on your own, even if you feel well or experience side effects. Discuss any concerns about your treatment with your oncologist, who can adjust the dose or manage side effects while maintaining your cancer therapy.
What Are the Side Effects of Erlotinib Krka?
Quick Answer: The most common side effects are skin rash and diarrhoea (affecting more than 1 in 10 patients). Serious side effects include interstitial lung disease, liver damage, and gastrointestinal perforation. Contact your doctor immediately if you experience sudden breathing difficulties, severe abdominal pain, or jaundice.
Like all medicines, Erlotinib Krka can cause side effects, although not everybody gets them. Many side effects are manageable with supportive care and dose adjustments. Your oncologist will monitor you regularly and can recommend treatments to help manage common side effects. It is important to report any new or worsening symptoms to your medical team promptly.
The skin rash associated with erlotinib is one of the most characteristic side effects of EGFR inhibitors. It typically appears within the first 1–2 weeks of treatment, most commonly on the face, scalp, chest, and back. Interestingly, clinical evidence suggests that the development and severity of skin rash may correlate with treatment response — patients who develop a rash may have better outcomes. Sun-exposed areas are particularly affected, so protective clothing and mineral-based sunscreen are recommended during treatment.
Very Common
May affect more than 1 in 10 people
- Skin rash (may worsen with sun exposure)
- Diarrhoea
- Nausea and vomiting
- Loss of appetite and weight loss
- Fatigue, fever, chills
- Infection
- Headache
- Altered skin sensation or numbness in extremities (neuropathy)
- Breathing difficulties and cough
- Mouth irritation (stomatitis)
- Abdominal pain, indigestion, and flatulence
- Abnormal liver function tests
- Itching (pruritus)
- Depression
- Eye irritation (keratoconjunctivitis)
Common
May affect up to 1 in 10 people
- Dry skin
- Hair loss (alopecia)
- Nosebleeds (epistaxis)
- Gastrointestinal bleeding
- Inflammatory reactions around fingernails (paronychia)
- Inflammation of hair follicles (folliculitis)
- Acne
- Skin cracks (fissures)
- Conjunctivitis or keratitis
- Impaired kidney function (when combined with chemotherapy)
Uncommon
May affect up to 1 in 100 people
- Interstitial lung disease (higher incidence in Japanese patients)
- Gastrointestinal perforation
- Kidney inflammation (nephritis)
- Excess protein in urine (proteinuria)
- Changes in eyelashes
- Increased body hair (hirsutism)
- Skin hyperpigmentation
- Changes in eyebrows
- Brittle or loose nails
Rare to Very Rare
May affect up to 1 in 1,000 people or fewer
- Hepatitis and liver failure (potentially life-threatening)
- Hand-foot syndrome (palmar-plantar erythrodysesthesia)
- Corneal ulceration or perforation
- Stevens-Johnson syndrome (severe blistering or peeling of skin)
- Iritis (inflammation of the coloured part of the eye)
Contact your doctor or seek emergency care immediately if you experience: sudden onset of breathing difficulties with cough and fever (possible interstitial lung disease); severe abdominal pain (possible gastrointestinal perforation); jaundice, dark urine, or persistent nausea/vomiting (possible liver damage); severe or persistent diarrhoea leading to dehydration; or severe blistering or peeling of the skin.
Side effects can often be managed through dose adjustments and supportive care. Your doctor may reduce the dose in 50 mg steps, temporarily interrupt treatment, or prescribe additional medications to manage symptoms. For skin rash, moisturisers, topical treatments, and sun protection are commonly recommended. For diarrhoea, early treatment with loperamide and adequate hydration are key management strategies.
How Should You Store Erlotinib Krka?
Quick Answer: Store Erlotinib Krka in its original blister packaging, protected from moisture. Keep out of the sight and reach of children. Do not use after the expiry date printed on the carton.
Proper storage of Erlotinib Krka is important to maintain the quality and effectiveness of the medication. Keep the tablets in the original blister packaging until ready to use, as the product is moisture-sensitive. No special temperature storage conditions are required, but general pharmaceutical storage principles apply — store in a cool, dry place away from direct sunlight and extreme temperatures.
Keep this medicine out of the sight and reach of children at all times. Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
Do not dispose of unused medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment and prevent accidental exposure. Many pharmacies and healthcare facilities offer medication take-back programmes for safe disposal of unused or expired cancer medications.
What Does Erlotinib Krka Contain?
Quick Answer: Each tablet contains erlotinib (as hydrochloride) as the active substance, available in 25 mg, 100 mg, and 150 mg strengths. The tablets are film-coated and come in blister packs of 30 or 60 tablets.
The active substance in Erlotinib Krka is erlotinib, present as erlotinib hydrochloride. The amount of erlotinib varies by tablet strength:
- 25 mg tablets: Pale yellow, round, slightly biconvex film-coated tablets with bevelled edges, debossed with “25” on one side. Diameter approximately 6 mm.
- 100 mg tablets: Pale orange-pink, round, slightly biconvex film-coated tablets with bevelled edges, debossed with “100” on one side. Diameter approximately 11 mm.
- 150 mg tablets: White to off-white, round, biconvex film-coated tablets with bevelled edges, debossed with “150” on one side. Diameter approximately 12 mm.
Inactive ingredients (excipients):
- Tablet core: Lactose monohydrate, microcrystalline cellulose (E460), hydroxypropylcellulose (E463), sodium laurilsulfate, sodium starch glycolate (Type A), calcium silicate (E552), magnesium stearate (E470b).
- Film coating: Hypromellose (E464), propylene glycol (E1520), titanium dioxide (E171), talc (E553b), red iron oxide (E172) (100 mg only), yellow iron oxide (E172) (25 mg and 100 mg only).
Erlotinib Krka is available in blister packs containing 30 or 60 film-coated tablets per carton. Not all pack sizes may be marketed in every country. The marketing authorisation holder and manufacturer is KRKA, d.d., Novo mesto, Slovenia.
Frequently Asked Questions About Erlotinib Krka
Erlotinib Krka is used to treat two types of cancer in adults. Its primary indication is advanced non-small cell lung cancer (NSCLC) in patients whose tumours have specific EGFR (epidermal growth factor receptor) mutations. It can be used as a first-line treatment or after previous chemotherapy. It is also used in combination with gemcitabine for the treatment of metastatic pancreatic cancer. EGFR mutation testing is required before starting treatment for NSCLC.
No, erlotinib must be taken on an empty stomach. Take the tablet at least 1 hour before or 2 hours after eating. Food significantly increases the absorption of erlotinib, which can lead to higher blood levels and more side effects. Maintaining consistent timing relative to meals helps ensure stable drug levels throughout the day.
The most common side effects are skin rash and diarrhoea, both occurring in more than 1 in 10 patients. Other very common side effects include nausea, loss of appetite, fatigue, infection, and abnormal liver function tests. The skin rash typically appears within the first 1–2 weeks and may actually be associated with better treatment response. Most side effects can be managed with supportive care and dose adjustments.
Yes, smoking significantly reduces the effectiveness of erlotinib. Cigarette smoke induces the CYP1A2 enzyme, which metabolises erlotinib, leading to substantially lower drug levels in the blood. Studies have shown that current smokers may have 50–60% lower erlotinib exposure compared to non-smokers. Patients are strongly advised to stop smoking before and during erlotinib treatment to achieve optimal therapeutic benefit.
Erlotinib is most effective against tumours harbouring activating EGFR mutations, particularly exon 19 deletions (del19) and the exon 21 L858R point mutation. These two mutation types account for approximately 85–90% of all EGFR-sensitising mutations. EGFR mutation testing (usually performed on a tumour biopsy sample or liquid biopsy) is mandatory before starting erlotinib for NSCLC. The T790M resistance mutation, which can develop during treatment, confers resistance to erlotinib and typically requires a switch to a third-generation EGFR inhibitor such as osimertinib.
Proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, and lansoprazole should be avoided during erlotinib treatment. PPIs raise gastric pH, which significantly reduces erlotinib absorption because the drug requires an acidic environment to dissolve properly. If acid-reducing therapy is needed, antacids (such as aluminium or magnesium hydroxide) can be used but should be taken at least 2 hours before or 1 hour after erlotinib. Discuss alternatives with your doctor.
References and Sources
All medical information on this page is based on peer-reviewed research, international clinical guidelines, and regulatory documents. The following sources were consulted:
- European Medicines Agency (EMA). Erlotinib — Summary of Product Characteristics. Available at: www.ema.europa.eu.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025.
- Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(10):907–958.
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–1966.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Available at: www.who.int.
- British National Formulary (BNF). Erlotinib. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in oncology, pulmonology, and clinical pharmacology. All content follows international medical guidelines and the GRADE evidence framework.
iMedic Medical Editorial Team — Specialists in oncology and clinical pharmacology with experience in targeted cancer therapies and patient education.
iMedic Medical Review Board — Independent panel of oncologists and pharmacologists who verify clinical accuracy according to EMA, NCCN, and ESMO guidelines.
Conflict of Interest Declaration: The iMedic Medical Editorial Team has no financial relationships with pharmaceutical companies. All content is independently produced without commercial funding or sponsorship.
Editorial Process: All drug information articles undergo a multi-step review process including initial medical writing, clinical accuracy review by specialist physicians, fact-checking against regulatory documents (EMA SmPC, FDA labelling), and final editorial review for clarity and accessibility. Content is updated when new evidence or regulatory changes emerge.